Brokerages Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) PT at $523.75

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $523.75.

Several equities research analysts have issued reports on IDXX shares. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a report on Monday, April 14th. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th.

IDEXX Laboratories Stock Down 1.0 %

IDXX traded down $4.32 on Monday, hitting $432.65. 1,400,269 shares of the company were exchanged, compared to its average volume of 638,429. The company has a market cap of $35.06 billion, a PE ratio of 40.55, a PEG ratio of 3.41 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories has a 12 month low of $356.14 and a 12 month high of $548.88. The stock's fifty day moving average is $419.27 and its 200-day moving average is $428.56.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.98% of the company's stock.

Institutional Trading of IDEXX Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the business. Norges Bank purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $412,258,000. GAMMA Investing LLC grew its holdings in IDEXX Laboratories by 59,810.7% during the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock valued at $3,856,950,000 after purchasing an additional 916,898 shares in the last quarter. Flossbach Von Storch SE lifted its holdings in IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after buying an additional 464,791 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of IDEXX Laboratories by 58.3% during the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock valued at $472,865,000 after acquiring an additional 414,802 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $156,412,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.